Role of angiotensin II in plasma PAI-1 changes induced by imidapril or candesartan in hypertensive patients with metabolic syndrome

Hypertension Research

Volumn 34, Issue 12, 2011, Pages 1321-1326

  Fogari, Roberto ^a   Zoppi, Annalisa ^a   Mugellini, Amedeo ^a   Maffioli, Pamela ^a   Lazzari, Pierangelo ^a   Derosa, Giuseppe ^a  

^a UNIVERSITY OF PAVIA   (Italy)

Author keywords

candesartan; fibrinolysis; imidapril; PAI 1

Indexed keywords

ANGIOTENSIN II; CANDESARTAN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; IMIDAPRIL; PLASMINOGEN ACTIVATOR INHIBITOR 1;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIASTOLIC BLOOD PRESSURE; DRUG DOSE TITRATION; ESSENTIAL HYPERTENSION; FEMALE; FIBRINOLYSIS; HUMAN; HUMAN TISSUE; HYPOTENSION; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; RANDOMIZED CONTROLLED TRIAL; SINGLE BLIND PROCEDURE; SYSTOLIC BLOOD PRESSURE;

ADOLESCENT; ADULT; AGED; ANGIOTENSIN II; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; BENZIMIDAZOLES; BLOOD GLUCOSE; BLOOD PRESSURE; BODY MASS INDEX; CHOLESTEROL; CHOLESTEROL, HDL; FEMALE; HUMANS; HYPERTENSION; IMIDAZOLIDINES; INSULIN; MALE; METABOLIC SYNDROME X; MIDDLE AGED; PLASMINOGEN ACTIVATOR INHIBITOR 1; TETRAZOLES; TRIGLYCERIDES; YOUNG ADULT;

EID: 82955188080     PISSN: 09169636     EISSN: 13484214     Source Type: Journal    
DOI: 10.1038/hr.2011.137     Document Type: Article

References (51)

1. Brown NJ, Agirbasli MA, Williams GH, Litchfield WR, Vaughan DE. Effect of activation and inhibition of the renin-angiotensin system on plasma PAI-1. Hypertension 1998; 32: 965-971. (Pubitemid 29001421)
2. Vaughan DE. Angiotensin, fibrinolysis and vascular homeostasis. Am J Cardiol 2001; 87: 18C-24C.
3. Ferrario CM, Strawn WB. Role of the renin-angiotensin-aldosterone system and pro-inflammatory mediators in cardiovascular disease. Am J Cardiol 2006; 98: 121-128. (Pubitemid 43902687)
4. Feener EP, Northrup JM, Aiello LP, King GL. Angiotensin II regulates the expression of plasminogen activator inhibitor-1 in cultured endothelial cells. J Clin Invest 1995; 95: 995-1001.
5. Gesualdo L, Ranieri E, Monno R, Rossiello MR, Colucci M, Semeraro N, Grandaliano G, Schena FP, Ursi M, Cerullo G. Angiotensin IV stimulates plasminogen activator inhibitor-1 expression in proximal tubular epithelial cells. Kidney Int 1999; 56: 461-470. (Pubitemid 29353143)
6. Skurk T, Lee YM, Hauner H. Angiotensin II and its metabolites stimulate PAI-1 protein release from human adipocytes in primary culture. Hypertension 2001; 37: 1336-1340. (Pubitemid 34163591)
7. Fintha A, Sebe A, Masszi A, Terebessy T, Huszar T, Rosivall L, Mucsi I. Angiotensin II activates plasminogen activator inhibitor-1 promoter in renal tubular epithelial cells via the AT1 receptor. Acta Physiol Hung 2007; 94: 19-30.
8. Ridker PM, Gaboury CL, Conlin PR, Seely EW, Williams GH, Vaughan DE. Stimulation of plasminogen activator inhibitor in vivo by infusion of angiotensin II: evidence of a potential interaction between the renin-angiotensin-system and fibrinolytic function. Circulation 1993; 87: 1969-1973. (Pubitemid 23165641)
9. Abrahamsen CT, Pullen MA, Schnackenberg CG, Grygielko ET, Edwards RM, Laping NJ, Brooks DP. Effects of angiotensin II and IV on blood pressure, renal function and PAI-1 expression in the heart and the kidney of the rat. Pharmacology 2002; 66: 26-30. (Pubitemid 34914114)
10. Brown NJ, Bradford J, Wang Z, Lea W, Ma L, Ma J, Vaughan DE, Fogo AB. Modulation of angiotensin II and norepinephrine-induced plasminogen activator inhibitor-1 expression by AT1a receptor deficiency. Kidney Int 2007; 72: 72-81. (Pubitemid 47014448)
11. Wright RA, Flapan AD, Alberti KG, Ludlam CA, Fox KA. Effects of captopril therapy on endogenous fibrinolysis in men with recent, uncomplicated, myocardial infarction. J Am Coll Cardiol 1994; 24: 67-73. (Pubitemid 24202778)
12. Vaughan DE, Roleau JL, Ridker PM, Arnold JM, Menapace FJ, Pfeffer MA. Effects of ramipril on plasma fibrinolytic balance in patients with acute anterior myocardial infarction: HEART Study Investigators. Circulation 1997; 96: 442-447. (Pubitemid 27329418)
13. Soejima H, Ogawa H, Yasue H, Suefuji H, Kaikita K, Nishiyama K. Effects of imidapril therapy on endogenous fibrinolysis in patients with recent myocardial infarction. Clin Cardiol 1997; 20: 441-445. (Pubitemid 27184937)
14. Sakata K, Shirotani M, Yoshida H, Urano T, Takada A. Differential effects of enalapril and nitrendipine on the fibrinolytic system in essential hypertension. Am Heart J 1999; 137: 1094-1099. (Pubitemid 30040734)
15. Lottermoser K, Wostmann B, Weisser B, Hertfelder HJ, Schmitz U, Vetter H, Dusing R. Effects of captopril on fibrinolytic function in healthy humans. Eur J Med Res 1999; 4: 31-34.
16. Fogari R, Preti P, Lazzari P, Corradi L, Zoppi A, Fogari E, Mugellini A. Effect of benazepril amlodipine combination on fibrinolysis in hypertensive diabetic patients. Eur J Clin Pharmacol 2003; 59: 271-275. (Pubitemid 37100344)
17. Seljeflot I, Moan A, Kjeldsen S, Sandvik E, Arnesen H. Effect of angiotensin II receptor blockade on fibrinolysis during acute hyperinsulinemia in patients with essential hypertension. Hypertension 1996; 27: 1299-1304. (Pubitemid 26165634)
18. Fogari R, Zoppi A, Malamani G, Marasi G, Pesce RM, Banderali A, Mugellini A. Effects of four angiotensin II-receptor antagonists on fibrinolysis in post-menopausal women with hypertension. Curr Ther Res 2001; 62: 68-78. (Pubitemid 32493032)
19. Skurk T, Lee YM, Nicuta-Rolfs TO, Haastert B, Wirth A, Hauner H. Effect of the angiotensin II receptor blocker candesartan on fibrinolysis in patients with mild hypertension. Diabetes Obes Metab 2004; 6: 56-62. (Pubitemid 38159730)
20. Lin TH, Voon WC, Yen HW, Huang CH, Su HM, Lai WT, Sheu SH. Lercanidipine and losartan effects on blood pressure and fibrinolytic parameters. Kaohsiung J Med Sci 2006; 22: 177-183.
21. Lottermoser K, Hertfelder HH, Vetter H, Dusing R. Fibrinolytic function in diureticinduced volume depletion. Am J Hypertens 2000; 13: 359-363. (Pubitemid 30312654)
22. Liu L, Zhao SP, Zhou HN, Li QZ, Li JX. Effect of fluvastatin and valsartan, alone and in combination, on post-prandial vascular inflammation and fibrinolytic activity in patients with essential hypertension. J Cardiovasc Pharmacol 2007; 50: 50-55. (Pubitemid 47220446)
23. Goodfield NE, Newby DE, Ludlam CA, Flapam AD. Effects of acute angiotensin II type 1 receptor antagonism and angiotensin converting enzyme inhibition on plasma fibrinolytic parameters in patients with heart failure. Circulation 1999; 99: 2983-2985. (Pubitemid 29270426)
24. Hirschl MM, Bur A, Woisetschlaeger C, Derhaschnig U, Laggner AN. Effects of candesartan and lisinopril on the fibrinolytic system in hypertensive patients. J Clin Hypertens 2007; 9: 430-435.
25. Brown NJ, Agirbasli M, Vaughan DE. Comparative effect of angiotensin converting enzyme inhibition and angiotensin II type 1 receptor antagonism on plasma fibrinolytic balance in humans. Hypertension 1999; 34: 285-290. (Pubitemid 29409229)
26. Fogari R, Zoppi A, Preti P, Fogari E, Malamani G, Mugellini A. Differential effects of ACE-inhibition and angiotensin II antagonism on fibrinolysis and insulin sensitività in hypertensive post-menopausal women. Am J Hypertens 2001; 14: 921-926. (Pubitemid 32862593)
27. Fogari R, Mugellini A, Zoppi A, Corradi L, Preti P, Lazzari P, Derosa G. Losartan and perindopril effects on plasma plasminogen activator inhibitor-1 and fibrinogen in hypertensive type 2 diabetics. Am J Hypertens 2002; 15: 316-320. (Pubitemid 34408970)
28. Paterna S, Di Garbo V, Avellone G, Di Pasquale P, Cacia A, Tuttolomondo A, Folloone G, Cardinale A, Maniscalchi T, Licata G. Effects of losartan and delapril on the fibrinolytic system in patients with mild to moderate hypertension. Clin Drug Invest 2003; 23: 717-724. (Pubitemid 37373793)
29. Fogari R, Zoppi A, Salvadeo SA, Mugellini A, Lazzari P, Santoro T, Derosa G. Fibrinolysis and insulin sensitivity in imidapril and candesartan (FISIC study) recipients with hypertension. Hypertens Res 2011; 34: 509-515.
30. Hubner R, Hogemann AM, Sunzel M, Riddel JG. Pharmacokinetics of candesartan after single and repeated doses of candesartan cilexetil in young and elderly healthy volunteers. J Hum Hypertens 1997; 11: S19-S25. (Pubitemid 27464501)
31. Johnston CI, Naitoh M, Burrell LM. Rationale and pharmacology of angiotensin II receptor antagonists: current status and future issues. J Hypertens 1997; 15: S3-S8.
32. Bindschedler M, Degen P, Flesch G, De Gasparo M, Preiswerk G. Pharmacokinetic and pharmacodynamic interaction of single oral doses of valsartan and furosemide. Eur J Clin Pharmacol 1997; 52: 371-378. (Pubitemid 27341937)
33. Shibasaki Y, Masaki H, Nishiue T, Nishikawa M, Matsubara H, Iwasaka T. Angiotensin II type 1 receptor antagonist, losartan, causes regression of left ventricular hypertrophy in end-stage renal disease. Nephron 2002; 90: 256-261. (Pubitemid 34195751)
34. Gradman AH, Pinto R, Kad R. Current concepts: renin inhibition in the treatment of hypertension. Curr Opin Pharmacol 2008; 8: 120-126. (Pubitemid 351372992)
35. Poli KA, Tofler GH, Larson MG, Evans JC, Sutherland PA, Lipinska I, Mittleman MA, Muller JE, D'Agostino RB, Wilson PW, Levy D. Association of BP with fibrinolytic potential in the Framingham Offspring Population. Circulation 2000; 101: 264-269. (Pubitemid 30054153)
36. Juan Vague I, Alessi MC. PAI-1, obesity, insulin resistance and risk of cardiovascular events. Thromb Haemost 1997; 78: 656-660. (Pubitemid 27289322)
37. Hansson L, Hedner T, Dahlof B. Prospective, randomized, open label, blinded end-point (PROBE) study: a novel design for intervention trials. Blood Press 1992; 1: 113-114.
38. Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel RH, Franklin BA, Gordon DJ, Krauss RM, Savage PJ, Smith Jr SC, Spertus JA. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung and Blood Institute Scientific Statement. Circulation 2005; 112: 2735-2752. (Pubitemid 41532612)
39. Schmieder RE, Langenfeld MRW, Friedrich A, Schobel HP, Gatzka CD, Weihprecht H. Angiotensin II related to sodium excretion modulates left ventricular structure in human essential hypertension. Circulation 1996; 94: 1304-1309. (Pubitemid 26307257)
40. Brown NJ, Kumar S, Painter CA, Vaughan DE. Ace inhibition versus angiotensin type 1 receptor antagonism. Differential effects on PAI-1 over time. Hypertension 2002; 40: 859-865. (Pubitemid 35434907)
41. Fogari R, Zoppi A, Mugellini A, Lazzari P, Derosa G. Different effects of aliskiren and losartan on fibrinolysis and insulin sensitivity in hypertensive patients with metabolic syndrome. Horm Metab Res 2010; 42: 892-896.
42. Folsom AR, Quamhieh DT, Wing RR, Jeffrey RW, Stinson VL, Kuller LH, Wu KK. Impact of weight loss on plasminogen activator inhibitor (PAI-1), factor VII and other hemostatic factors in moderately overweight adults. Arterioscler Thromb Vasc Biol 1993; 13: 162-169. (Pubitemid 23056789)
43. Mertens I, Van Gaal LF. Obesity, haemostasis and the fibrinolytic system. Obes Rev 2002; 3: 85-101. (Pubitemid 34827150)
44. Kerins DM, Hao Q, Vaughan DE. Angiotensin induction of PAI-1 expression in endothelial cells is mediated by the hexapeptide angiotensin IV. J Clin Invest 1995; 96: 2515-2520.
45. Numaguchi Y, Ishii M, Kubota R, Morita Y, Yamamoto K, Matsushita T, Okumura K, Murohara T. Ablation of angiotensin IV receptor attenuates hypofibrinolysis via PAI-1 downregulation and reduces occlusive arterial thrombosis. Arterioscler Thromb Vasc Biol 2009; 29: 2012-2018.
46. Moeller I, Clune EF, Fennessy PA, Bingley JA, Albiston AL, Mendelsohn FA, Chai SY. Up-regulation of AT4 receptor levels in carotid arteries following balloon injury. Regul Pept 1999; 83: 25-30. (Pubitemid 29378362)
47. Johnston CI. Angiotensin converting enzyme inhibitors. In Nicholls MG, Robertson JIS (eds), The Renin-Angiotensin System. London, Gower, 1993, pp 871-8715.
48. Blood Pressure Lowering Treatment Trialists' Collaboration. Blood pressure-dependent and independent effects of agents that inhibit the renin-angiotensin system. J Hypertens 2007; 25: 951-958.
49. Minai K, Matsumoto T, Horie H, Ohira N, Takashima H, Yokohama H, Kinoshita M. Bradykinin stimulates the release of tissue plasminogen activator in human coronary circulation: effects of angiotensin converting enzyme inhibitors. J Am Coll Cardiol 2001; 37: 1565-1570.
50. Pretorius M, Rosenbaum D, Vaughan DE, Brown NJ. Angiotensin converting enzyme inhibition increases human vascular tissue plasminogen activator release through endogenous bradykinin. Circulation 2003; 107: 579-585. (Pubitemid 36176808)
51. Matsumoto T, Takashima H, Nakae I, Yamane T, Hayashi H, Horie M. Angiotensinconverting enzyme inhibition augments coronary release of tissue plasminogen activator in women but not in men. Hypertension 2010; 56: 364-368.